Ioannis Vrettos, Panagiota Voukelatou, Apostolos Katsoras, Despoina Theotoka, Andreas Kalliakmanis
{"title":"老年患者多药相关疾病","authors":"Ioannis Vrettos, Panagiota Voukelatou, Apostolos Katsoras, Despoina Theotoka, Andreas Kalliakmanis","doi":"10.1155/2017/4276047","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Polypharmacy in several cases is deemed necessary and elderly patients are prone to this phenomenon. The objective of this study was to identify the prevalence and the predictors of polypharmacy among consecutively unplanned admissions of patients aged ≥65 years.</p><p><strong>Patients and methods: </strong>In 310 patients (51% women), mean age 80.24 years (95% CI 79.35-81.10), demographic characteristics, medical history, medications, and cause of admission were recorded. Parametric tests and multiple logistic regression analysis were applied to identify the factors that have significant association with polypharmacy.</p><p><strong>Results: </strong>53.5% of patients belonged to polypharmacy group. In multivariate analysis the independent predictors of polypharmacy were arterial hypertension (<i>p</i> = 0.003, OR = 2.708, and 95% CI 1.400-5.238), coronary artery disease (<i>p</i> = 0.001, OR = 8.274, and 95% CI 3.161-21.656), heart failure (<i>p</i> = 0.030, OR = 4.042, and 95% CI 1.145-14.270), atrial fibrillation (<i>p</i> = 0.031, OR = 2.477, and 95% CI 1.086-5.648), diabetes mellitus (<i>p</i> = 0.010, OR = 2.390, and 95% CI 1.232-4.636), dementia (<i>p</i> = 0.001, OR = 4.637, and 95% CI 1.876-11.464), and COPD (<i>p</i> = 0.022, OR = 3.626, and 95% CI 1.208-10.891).</p><p><strong>Conclusions: </strong>Polypharmacy mainly was linked to cardiovascular diseases. If deprescribing is not feasible, physicians must oversee those patients in order to recognise early, possible drug reactions.</p>","PeriodicalId":39066,"journal":{"name":"Current Gerontology and Geriatrics Research","volume":"2017 ","pages":"4276047"},"PeriodicalIF":0.0000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2017/4276047","citationCount":"26","resultStr":"{\"title\":\"Diseases Linked to Polypharmacy in Elderly Patients.\",\"authors\":\"Ioannis Vrettos, Panagiota Voukelatou, Apostolos Katsoras, Despoina Theotoka, Andreas Kalliakmanis\",\"doi\":\"10.1155/2017/4276047\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Polypharmacy in several cases is deemed necessary and elderly patients are prone to this phenomenon. The objective of this study was to identify the prevalence and the predictors of polypharmacy among consecutively unplanned admissions of patients aged ≥65 years.</p><p><strong>Patients and methods: </strong>In 310 patients (51% women), mean age 80.24 years (95% CI 79.35-81.10), demographic characteristics, medical history, medications, and cause of admission were recorded. Parametric tests and multiple logistic regression analysis were applied to identify the factors that have significant association with polypharmacy.</p><p><strong>Results: </strong>53.5% of patients belonged to polypharmacy group. In multivariate analysis the independent predictors of polypharmacy were arterial hypertension (<i>p</i> = 0.003, OR = 2.708, and 95% CI 1.400-5.238), coronary artery disease (<i>p</i> = 0.001, OR = 8.274, and 95% CI 3.161-21.656), heart failure (<i>p</i> = 0.030, OR = 4.042, and 95% CI 1.145-14.270), atrial fibrillation (<i>p</i> = 0.031, OR = 2.477, and 95% CI 1.086-5.648), diabetes mellitus (<i>p</i> = 0.010, OR = 2.390, and 95% CI 1.232-4.636), dementia (<i>p</i> = 0.001, OR = 4.637, and 95% CI 1.876-11.464), and COPD (<i>p</i> = 0.022, OR = 3.626, and 95% CI 1.208-10.891).</p><p><strong>Conclusions: </strong>Polypharmacy mainly was linked to cardiovascular diseases. If deprescribing is not feasible, physicians must oversee those patients in order to recognise early, possible drug reactions.</p>\",\"PeriodicalId\":39066,\"journal\":{\"name\":\"Current Gerontology and Geriatrics Research\",\"volume\":\"2017 \",\"pages\":\"4276047\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1155/2017/4276047\",\"citationCount\":\"26\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Gerontology and Geriatrics Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2017/4276047\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2017/12/25 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Gerontology and Geriatrics Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2017/4276047","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/12/25 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 26
摘要
在一些情况下,多重用药被认为是必要的,老年患者容易出现这种现象。本研究的目的是确定年龄≥65岁的连续非计划入院患者中多药的患病率和预测因素。患者和方法:310例患者(51%为女性),平均年龄80.24岁(95% CI 79.35-81.10),记录人口统计学特征、病史、用药和入院原因。采用参数检验和多元逻辑回归分析确定与多药相关的因素。结果:53.5%的患者属于综合用药组。在多变量分析的独立预测因子复方用药是动脉高血压(p = 0.003, = 2.708, 95% CI 1.400 - -5.238),冠状动脉疾病(p = 0.001, = 8.274, 95% CI 3.161 - -21.656),心力衰竭(p = 0.030, = 4.042, 95% CI 1.145 - -14.270),心房纤颤(p = 0.031, = 2.477, 95% CI 1.086 - -5.648)、糖尿病(p = 0.010, = 2.390, 95% CI 1.232 - -4.636),老年痴呆症(p = 0.001, = 4.637, 95% CI 1.876 - -11.464),和慢性阻塞性肺病(p = 0.022,OR = 3.626, 95% CI 1.208-10.891)。结论:多药联用主要与心血管疾病有关。如果处方不可行,医生必须监督这些病人,以便及早发现可能的药物反应。
Diseases Linked to Polypharmacy in Elderly Patients.
Introduction: Polypharmacy in several cases is deemed necessary and elderly patients are prone to this phenomenon. The objective of this study was to identify the prevalence and the predictors of polypharmacy among consecutively unplanned admissions of patients aged ≥65 years.
Patients and methods: In 310 patients (51% women), mean age 80.24 years (95% CI 79.35-81.10), demographic characteristics, medical history, medications, and cause of admission were recorded. Parametric tests and multiple logistic regression analysis were applied to identify the factors that have significant association with polypharmacy.
Results: 53.5% of patients belonged to polypharmacy group. In multivariate analysis the independent predictors of polypharmacy were arterial hypertension (p = 0.003, OR = 2.708, and 95% CI 1.400-5.238), coronary artery disease (p = 0.001, OR = 8.274, and 95% CI 3.161-21.656), heart failure (p = 0.030, OR = 4.042, and 95% CI 1.145-14.270), atrial fibrillation (p = 0.031, OR = 2.477, and 95% CI 1.086-5.648), diabetes mellitus (p = 0.010, OR = 2.390, and 95% CI 1.232-4.636), dementia (p = 0.001, OR = 4.637, and 95% CI 1.876-11.464), and COPD (p = 0.022, OR = 3.626, and 95% CI 1.208-10.891).
Conclusions: Polypharmacy mainly was linked to cardiovascular diseases. If deprescribing is not feasible, physicians must oversee those patients in order to recognise early, possible drug reactions.